Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers
Open Access
- 6 July 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 125 (8), 1068-1079
- https://doi.org/10.1038/s41416-021-01425-7
Abstract
Immune checkpoint inhibitors (ICIs) have altered the treatment paradigm across a range of tumour types, including gastro-oesophageal cancers. For patients with any cancer type who respond, ICIs can confer long-term disease control and significantly improve survival and quality of life, but for patients with gastro-oesophageal cancer, ICIs can be transformative, as durable responses in advanced disease have hitherto been rare, especially in those patients who are resistant to first-line cytotoxic therapies. Results from trials in patients with advanced-stage gastro-oesophageal cancer have raised hopes that ICIs will be successful as adjuvant and neoadjuvant treatments in early-stage disease, when the majority of patients relapse after potential curative treatments, and several trials are ongoing. Unfortunately, however, ICI-responding patients appear to constitute a minority subgroup within gastro-oesophageal cancer, and resistance to ICI therapy (whether primary or acquired) is common. Understanding the biological mechanisms of ICI resistance is a current major research challenge and involves investigation of both tumour and patient-specific factors. In this review, we discuss the mechanisms underlying ICI resistance and their potential specific applications of this knowledge towards precision medicine strategies in the management of gastro-oesophageal cancers in clinical practice.Keywords
This publication has 123 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Involvement of CXCR4 Chemokine Receptor in Metastastic HER2-Positive Esophageal CancerPLOS ONE, 2012
- Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13Cancer Immunology, Immunotherapy, 2011
- Regulatory T cells and Foxp3Immunological Reviews, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and functionTrends in Immunology, 2011
- The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinomaMolecular Cancer, 2010
- Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseasesNature Reviews Immunology, 2010
- Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer ImmunotherapyClinical Cancer Research, 2010
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerThe New England Journal of Medicine, 2008